RxDoctor Payments Data

Isabel Hamro, APRN

Family · Naples, FLNPI 1013420736

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 49 payments — averaging $43.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$503
  • Madrigal Pharmaceuticals$290
  • Johnson & Johnson$256
  • Aimmune Therapeutics, Inc.$189
  • Lilly USA, LLC$150
  • Ardelyx, Inc.$139
  • plus $607 from 9 others

What the payments were for

  • Food & beverage$2,11499%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,134 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$50,137
Medicare patients
395
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase14$28,024
LinzessLinaclotide12$8,696
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$3,855
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C17$2,535
CholestyramineCholestyramine (With Sugar)21$1,672
Famotidine64$1,315
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl68$978
Pantoprazole Sodium96$906
Esomeprazole Magnesium45$623
Lactulose13$249
Omeprazole15$190
Dicyclomine Hcl11$143
Ondansetron Hcl11$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$503$36,71926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →